Beyond Verbal
Beyond Verbal is an Israeli-founded company specializing in voice analysis technology.
Profile
Develops medical devices and biopharmaceuticals that use nitric oxide to treat respiratory conditions and cancer.
Beyond Verbal is an Israeli-founded company specializing in voice analysis technology. The company's origins trace back to research on vocal biomarkers at Tel Aviv University, with its commercial launch focused on decoding emotions and health signals from speech patterns. Its flagship product, LungFit PH, is a tankless nitric oxide delivery system for hospital use, which saw a 105% year-over-year revenue increase to $2.2 million in fiscal Q3 2026.
The company maintains fiscal year 2026 revenue guidance of $8-10 million and reported a pro forma cash balance of $22.3 million as of December 2025, including proceeds from a January 2026 private placement. Beyond Air, its subsidiary, is advancing a second-generation LungFit PH system pending FDA clearance, targeting reduced weight and footprint for broader hospital adoption. The company also explores nitric oxide applications in oncology through its UNO program, with Phase 1a data in solid tumors slated for presentation at the AACR 2026 Annual Meeting. A recent strategic move includes a binding letter of intent for XTL Biopharmaceuticals to acquire 85% of Beyond Air's NeuroNOS subsidiary, potentially bringing in up to $32.5 million in upfront cash, milestones, and equity.
Who buys this
- Hospitals and healthcare providers
- VA Medical Centers
- International medical distributors
- Biopharmaceutical partners
Strengths and what to watch
Strengths
- Proprietary tankless nitric oxide delivery system (LungFit PH) with FDA-cleared applications
- 105% YoY revenue growth in fiscal Q3 2026, demonstrating commercial traction
- Dual pipeline with both medical device and biopharmaceutical applications of nitric oxide technology
Watch for
- Dependence on FDA clearance for second-generation LungFit PH system to drive next growth phase
- High cash burn rate despite recent funding, with $22.3 million pro forma balance expected to last only into 2027
- Execution risk in spinning out NeuroNOS subsidiary while maintaining focus on core respiratory business
Recent moves
Key Information
- Founded
- 2012
- Headquarters
- Tel Aviv, Tel Aviv
Frequently Asked Questions
What is Beyond Verbal and what do they specialize in?
Beyond Verbal develops medical devices and biopharmaceuticals using nitric oxide, primarily for respiratory conditions and cancer. Their flagship product, LungFit PH, is a tankless nitric oxide delivery system for hospitals, with additional research in voice analysis technology for health monitoring.
How successful is Beyond Verbal's LungFit PH system?
LungFit PH achieved 105% year-over-year revenue growth to $2.2 million in fiscal Q3 2026. The company maintains $8-10 million revenue guidance for 2026 and is developing a second-generation system pending FDA clearance for broader hospital adoption.
What are Beyond Verbal's financial prospects?
Beyond Verbal reported $22.3 million pro forma cash balance as of December 2025, with funding expected to last until 2027. The NeuroNOS subsidiary acquisition could bring $32.5 million in upfront cash and milestones, supporting ongoing R&D and commercialization efforts.
How is Beyond Verbal expanding beyond respiratory treatments?
Through its UNO program, Beyond Verbal explores nitric oxide applications in oncology, with Phase 1a solid tumor data to be presented at AACR 2026. This complements their core respiratory business with potential cancer therapy innovations.
What risks does Beyond Verbal face?
Key challenges include dependence on FDA clearance for their next-gen LungFit PH system, high cash burn rates despite recent funding, and execution risks in managing the NeuroNOS subsidiary spin-off while advancing core respiratory treatments.
Who are Beyond Verbal's main customers?
Primary customers include hospitals, VA Medical Centers, and international medical distributors. Their biopharmaceutical partnerships also target oncology applications, creating multiple revenue streams across healthcare providers and research institutions.
Sources
- finance.yahoo.com — Q3 2026 financial results and corporate updates
- techcrunch.com — General technology industry context
- www.sec.gov — Market context for AI and healthcare technology
- www.hpe.com — Healthcare technology implementation benchmarks